Good afternoon :)
Place Order
Add to Watchlist

Auro Laboratories Ltd

AUROLAB

Auro Laboratories Ltd

AUROLAB
Health CarePharmaceuticals
SmallcapWith a market cap of ₹129 cr, stock is ranked 2,804
High RiskStock is 3.58x as volatile as Nifty
197.804.81% (-10.00)
197.804.81% (-10.00)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹129 cr, stock is ranked 2,804
High RiskStock is 3.58x as volatile as Nifty

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹129 cr, stock is ranked 2,804
High RiskStock is 3.58x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
21.013.09
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
49.796.290.52%

Forecast & Ratings

Detailed Forecast 
Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Auro Laboratories Limited is engaged in the business of bulk drugs. It manufactures active pharmaceutical ingredients (APIs), intermediates and generic formulations.

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Lower than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 2.91%, vs industry avg of 9.03%

Decreasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share decreased from 0.02% to 0.01%

Lower than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 12.1%, vs industry avg of 15.28%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue28.3336.0041.3047.7844.7655.0151.9653.8355.1440.19
Raw Materialssubtract16.3820.0824.6630.3923.9927.6433.7637.3029.0430.33
Power & Fuel Costsubtract1.021.291.481.641.691.601.672.082.43
Employee Costsubtract2.372.722.802.873.483.643.703.763.91
Selling & Administrative Expensessubtract2.582.523.274.185.035.845.864.737.31
Operating & Other expensessubtract2.764.442.230.753.334.291.250.630.28
Depreciation/Amortizationsubtract0.680.860.931.011.021.041.021.071.091.09
Interest & Other Itemssubtract1.661.181.210.870.580.460.830.810.740.65
Taxes & Other Itemssubtract0.002.111.191.671.583.321.031.002.551.95
EPS1.411.285.667.066.5111.524.563.9312.509.90
DPS0.000.000.000.000.000.000.000.000.000.00
Payout ratio0.000.000.000.000.000.000.000.000.000.00

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Auro Laboratories Ltd16.643.09
Sun Pharmaceutical Industries Ltd44.576.360.76%
Cipla Ltd29.504.540.86%
Torrent Pharmaceuticals Ltd63.6815.380.90%

Price Comparison

Compare AUROLAB with any stock or ETF
Compare AUROLAB with any stock or ETF
AUROLAB
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding52.15%0.01%0.00%0.00%47.84%

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Shareholding History

JunSepDec '23MarJunSep0.00%0.00%0.00%0.00%0.00%0.00%

Insider Trades & Bulk Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No Dividends

Dividends are the portion of earnings that a company distributes to all its shareholders every year

AUROLAB has not given any dividends in last 5 years

Dividends

Corp. Actions

Announcements

Legal Orders

Dividends

Hmm, looks like data is unavailable here. Please come back after some time
News & Opinions
Earnings
Auro Laboratories standalone net profit declines 81.73% in the September 2024 quarter

Net profit of Auro Laboratories declined 81.73% to Rs 0.36 crore in the quarter ended September 2024 as against Rs 1.97 crore during the previous quarter ended September 2023. Sales declined 76.88% to Rs 3.10 crore in the quarter ended September 2024 as against Rs 13.41 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales3.1013.41 -77 OPM %23.2322.60 - PBDT0.753.00 -75 PBT0.482.73 -82 NP0.361.97 -82 Powered by Capital Market - Live

2 days agoCapital Market - Live
Corporate
Auro Laboratories to hold board meeting

Auro Laboratories will hold a meeting of the Board of Directors of the Company on 11 November 2024Powered by Capital Market - Live

1 week agoCapital Market - Live
Earnings
Auro Laboratories standalone net profit rises 5.63% in the June 2024 quarter

Net profit of Auro Laboratories rose 5.63% to Rs 0.75 crore in the quarter ended June 2024 as against Rs 0.71 crore during the previous quarter ended June 2023. Sales declined 43.81% to Rs 5.72 crore in the quarter ended June 2024 as against Rs 10.18 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales5.7210.18 -44 OPM %23.0811.39 - PBDT1.271.25 2 PBT1.000.98 2 NP0.750.71 6 Powered by Capital Market - Live

3 months agoCapital Market - Live
Corporate
Auro Laboratories to announce Quarterly Result

Auro Laboratories will hold a meeting of the Board of Directors of the Company on 9 August 2024Powered by Capital Market - Live

3 months agoCapital Market - Live